ADMA BIOLOGICS, INC. Operating Lease, Expense
ADMA BIOLOGICS, INC. (ADMA) reported Operating Lease, Expense of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- ADMA BIOLOGICS, INC. operating lease, expense for the quarter ending 2026-06-30 was $500.00K, a 16.67% decline year-over-year.
- ADMA BIOLOGICS, INC. operating lease, expense for the quarter ending 2026-03-31 was $500.00K, a 16.67% decline year-over-year.
- ADMA BIOLOGICS, INC. operating lease, expense for the quarter ending 2025-12-31 was $600.00K, a 0.00% change year-over-year.
- ADMA BIOLOGICS, INC. operating lease, expense for the quarter ending 2025-09-30 was $600.00K, a 0.00% change year-over-year.
- ADMA BIOLOGICS, INC. operating lease, expense for fiscal 2025 was $2.40M, a 0.00% change from fiscal 2024.
- ADMA BIOLOGICS, INC. operating lease, expense for fiscal 2024 was $2.40M, a 0.00% change from fiscal 2023.
- ADMA BIOLOGICS, INC. operating lease, expense for fiscal 2023 was $2.40M, a 14.29% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. operating lease, expense for fiscal 2022 was $2.10M, a 50.00% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 6 month as first filed | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-08-05 | $1.00M 10-Q · filed 2026-08-05 | $1.60M derived: sum of 3 quarters · filed 2026-08-05 | $2.20M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $500.00K 10-Q · filed 2026-05-06 | $1.10M derived: sum of 2 quarters · filed 2026-05-06 | $1.70M derived: sum of 3 quarters · filed 2026-05-06 | $2.30M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.80M derived: sum of 3 quarters · filed 2026-08-05 | $2.40M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $600.00K 10-Q · filed 2025-11-05 | $1.20M derived: sum of 2 quarters · filed 2026-08-05 | $1.80M 10-Q · filed 2025-11-05 | $2.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $600.00K 10-Q · filed 2026-08-05 | $1.20M 10-Q · filed 2026-08-05 | $1.80M derived: sum of 3 quarters · filed 2026-08-05 | $2.40M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $600.00K 10-Q · filed 2026-05-06 | $1.20M derived: sum of 2 quarters · filed 2026-05-06 | $1.80M derived: sum of 3 quarters · filed 2026-05-06 | $2.40M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.80M derived: sum of 3 quarters · filed 2026-02-25 | $2.40M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $600.00K 10-Q · filed 2025-11-05 | $1.20M derived: sum of 2 quarters · filed 2025-11-05 | $1.80M 10-Q · filed 2025-11-05 | $2.40M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $600.00K 10-Q · filed 2025-08-06 | $1.20M 10-Q · filed 2025-08-06 | $1.80M derived: sum of 3 quarters · filed 2026-02-25 | $2.40M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $600.00K 10-Q · filed 2025-05-07 | $1.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.80M derived: sum of 3 quarters · filed 2026-02-25 | $2.40M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.20M derived: sum of 2 quarters · filed 2026-02-25 | $1.80M derived: sum of 3 quarters · filed 2026-02-25 | $2.40M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $600.00K 10-Q · filed 2024-11-07 | $1.20M derived: sum of 2 quarters · filed 2024-11-07 | $1.80M 10-Q · filed 2024-11-07 | $2.40M derived: sum of 4 quarters · filed 2025-03-18 | |
| 2023-06-30 | $600.00K 10-Q · filed 2024-08-08 | $1.20M 10-Q · filed 2024-08-08 | $1.80M derived: sum of 3 quarters · filed 2025-03-18 | $2.40M derived: sum of 4 quarters · filed 2025-03-18 | |
| 2023-03-31 | $600.00K 10-Q · filed 2024-05-09 | $1.20M derived: sum of 2 quarters · filed 2025-03-18 | $1.80M derived: sum of 3 quarters · filed 2025-03-18 | $2.30M derived: sum of 4 quarters · filed 2025-03-18 | |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.20M derived: sum of 2 quarters · filed 2025-03-18 | $1.70M derived: sum of 3 quarters · filed 2025-03-18 | $2.10M 10-K · filed 2025-03-18 | |
| 2022-09-30 | $600.00K 10-Q · filed 2023-11-08 | $1.10M derived: sum of 2 quarters · filed 2023-11-08 | $1.50M 10-Q · filed 2023-11-08 | $1.90M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-09 | $900.00K 10-Q · filed 2023-08-09 | $1.30M derived: sum of 3 quarters · filed 2024-02-28 | $1.70M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $400.00K 10-Q · filed 2023-05-10 | $800.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.20M derived: sum of 3 quarters · filed 2024-02-28 | $1.60M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $800.00K derived: sum of 2 quarters · filed 2024-02-28 | $1.20M derived: sum of 3 quarters · filed 2024-02-28 | $1.40M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $400.00K 10-Q · filed 2022-11-09 | $800.00K derived: sum of 2 quarters · filed 2022-11-09 | $1.00M 10-Q · filed 2022-11-09 | $1.40M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $400.00K 10-Q · filed 2022-08-10 | $600.00K 10-Q · filed 2022-08-10 | $700.00K 10-Q · filed 2021-08-11 | $1.00M derived: sum of 3 quarters · filed 2022-08-10 | $1.20M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $300.00K 10-Q · filed 2022-05-11 | $600.00K derived: sum of 2 quarters · filed 2022-05-11 | $800.00K derived: sum of 3 quarters · filed 2022-05-11 | $900.00K derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $500.00K derived: sum of 2 quarters · filed 2022-03-24 | $600.00K derived: sum of 3 quarters · filed 2022-03-24 | $700.00K 10-K · filed 2022-03-24 | |
| 2020-09-30 | $200.00K 10-Q · filed 2021-11-10 | $300.00K derived: sum of 2 quarters · filed 2021-11-10 | $400.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $100.00K 10-Q · filed 2021-08-11 | $200.00K 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |